Fontainebleau

Researchers are evaluating the impact of vaccine funding provided by the National Health Insurance on vaccination coverage among patients targeted by current vaccination recommendations. The study focuses on patients seen in outpatient consultations within four healthcare institutions in the Ile-de-France region in France. The project aims to determine if dedicated vaccine funding can improve vaccination rates for vulnerable patients at risk of infections, such as pregnant women for pertussis and eligible patients for pneumococcal vaccination. The study involves several groups including women in the immediate postpartum period, patients eligible for pneumococcal vaccination with specific health coverage, and healthcare providers involved in vaccination efforts. Questionnaires will be used to collect information from patients and healthcare providers. The study will assess vaccination coverage for pertussis and pneumococcal infections at 3 and 18 months, along with evaluating socio-economic factors, changes in healthcare professional practices, and improvements in communication about vaccination status using digital tools. Participants will be monitored through outpatient consultation records and questionnaires. Researchers will measure the number of vaccinated individuals, factors influencing vaccination, and the frequency of vaccination offers and administration by healthcare providers. The study will also observe changes in documentation practices to enhance communication between institutions and primary care. The research is expected to run until July 2027, with a focus on improving vaccine reimbursement and coverage policies based on findings.

Researchers are investigating kidney cancer through the UroCCR network, a national registry and research platform in France that collects detailed real-world data on patient care and disease progression. Established in 2011, this extensive database includes over 21,000 cases from 58 centers and links clinical information with annotated biological samples and national health data. The platform supports multiple types of research, including translational studies, clinical evaluations, and social science investigations, aiming to improve understanding and management of renal cell carcinoma. The study involves adult patients diagnosed with kidney cancer and documents their treatments, including procedures such as radical or partial nephrectomy as determined by the surgeon. Data collected encompasses clinical parameters, imaging, patient-reported outcomes, and socioeconomic factors. The registry supports prospective research projects and ancillary studies, with a focus on real-world practice following national guidelines. It also integrates digital tools for monitoring and prediction, enhancing personalized treatment strategies. Participants contribute data continuously from enrollment through long-term follow-up, which may last until death or withdrawal. The study collects comprehensive clinical, biological, imaging, and patient-reported information, along with biological samples like plasma, urine, and tumor tissue. Researchers measure outcomes related to research project promotion, biological sample collection, epidemiology, treatment monitoring, quality of life, biomarker research, and clinical practice evaluation. This ongoing data collection supports knowledge advancement and improved kidney cancer care over many years.